SM
RETA

SG3 Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

SG3 Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85,000
Closed -$2.79M – 938
2022
Q1 		$2.79M Buy
+85,000
New +$2.52M 0.08% 236
2021
Q3 		– Sell
-6,000
Closed -$849K – 1317
2021
Q2 		$849K Buy
+6,000
New +$678K 0.03% 517

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's RETA Position: Q4 2020 in Review

SG3 Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 1,500 shares — an estimated $146K sold.

SG3 Management first reported a position in RETA in Q1 2019 and held it in 5 quarters. The position peaked at $818K in Q4 2019. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

  • SG3 Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
  • SG3 Management sold 1,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $146K.
  • SG3 Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 5 quarters.
  • SG3 Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $818K in Q4 2019.
  • 202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.